182 related articles for article (PubMed ID: 33376135)
1. Transcriptome-Level Interactions between Budesonide and Formoterol Provide Insight into the Mechanism of Action of Inhaled Corticosteroid/Long-Acting
Mostafa MM; Rider CF; Wathugala ND; Leigh R; Giembycz MA; Newton R
Mol Pharmacol; 2021 Mar; 99(3):197-216. PubMed ID: 33376135
[TBL] [Abstract][Full Text] [Related]
2. Long-acting β
Altonsy MO; Mostafa MM; Gerber AN; Newton R
Am J Physiol Lung Cell Mol Physiol; 2017 Mar; 312(3):L358-L370. PubMed ID: 28039105
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells.
Mostafa MM; Rider CF; Shah S; Traves SL; Gordon PMK; Miller-Larsson A; Leigh R; Newton R
BMC Med Genomics; 2019 Jan; 12(1):29. PubMed ID: 30704470
[TBL] [Abstract][Full Text] [Related]
4. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells.
Kaur M; Chivers JE; Giembycz MA; Newton R
Mol Pharmacol; 2008 Jan; 73(1):203-14. PubMed ID: 17901197
[TBL] [Abstract][Full Text] [Related]
5. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.
Rider CF; Shah S; Miller-Larsson A; Giembycz MA; Newton R
PLoS One; 2015; 10(1):e0116773. PubMed ID: 25625944
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of long-acting β
Kim Y; Hou V; Huff RD; Aguiar JA; Revill S; Tiessen N; Cao Q; Miller MS; Inman MD; Ask K; Doxey AC; Hirota JA
Respir Res; 2021 Oct; 22(1):266. PubMed ID: 34666750
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects of
Yan D; Hamed O; Joshi T; Mostafa MM; Jamieson KC; Joshi R; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2018 Jul; 366(1):220-236. PubMed ID: 29653961
[TBL] [Abstract][Full Text] [Related]
9. Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention.
Aalbers R; Vogelmeier C; Kuna P
Respir Med; 2016 Feb; 111():1-7. PubMed ID: 26614594
[TBL] [Abstract][Full Text] [Related]
10. Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma.
Mori K; Fujisawa T; Inui N; Hashimoto D; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Toyoshima M; Imokawa S; Yamada T; Shirai T; Masuda M; Hayakawa H; Chida K; Suda T
Respir Med; 2016 Oct; 119():1-6. PubMed ID: 27692128
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.
Holden NS; Rider CF; Bell MJ; Velayudhan J; King EM; Kaur M; Salmon M; Giembycz MA; Newton R
Br J Pharmacol; 2010 May; 160(2):410-20. PubMed ID: 20423350
[TBL] [Abstract][Full Text] [Related]
12. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells.
Yamaya M; Nishimura H; Nadine L; Kubo H; Nagatomi R
Respir Investig; 2014 Jul; 52(4):251-60. PubMed ID: 24998372
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting
Rider CF; Altonsy MO; Mostafa MM; Shah SV; Sasse S; Manson ML; Yan D; Kärrman-Mårdh C; Miller-Larsson A; Gerber AN; Giembycz MA; Newton R
Mol Pharmacol; 2018 Sep; 94(3):1031-1046. PubMed ID: 29959223
[TBL] [Abstract][Full Text] [Related]
14. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
15. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.
Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T
Respir Investig; 2020 May; 58(3):155-168. PubMed ID: 32094077
[TBL] [Abstract][Full Text] [Related]
16. β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids.
Holden NS; Bell MJ; Rider CF; King EM; Gaunt DD; Leigh R; Johnson M; Siderovski DP; Heximer SP; Giembycz MA; Newton R
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19713-8. PubMed ID: 22080612
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication.
Marcellini A; Swieboda D; Guedán A; Farrow SN; Casolari P; Contoli M; Johnston SL; Papi A; Solari R
Eur J Pharmacol; 2021 Feb; 893():173839. PubMed ID: 33359650
[TBL] [Abstract][Full Text] [Related]
18. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
Tamm M; Richards DH; Beghé B; Fabbri L
Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
[TBL] [Abstract][Full Text] [Related]
19. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
20. Benefit-risk assessment of long-acting beta2-agonists in asthma.
Jackson CM; Lipworth B
Drug Saf; 2004; 27(4):243-70. PubMed ID: 15003036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
